White Pine Capital LLC Purchases 41,925 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)

White Pine Capital LLC grew its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 189.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,033 shares of the medical instruments supplier’s stock after purchasing an additional 41,925 shares during the quarter. White Pine Capital LLC’s holdings in AngioDynamics were worth $587,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of ANGO. SG Americas Securities LLC bought a new position in shares of AngioDynamics in the third quarter valued at about $103,000. CWM LLC increased its position in AngioDynamics by 981.3% during the third quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after acquiring an additional 8,832 shares during the period. Assenagon Asset Management S.A. increased its position in AngioDynamics by 7.2% during the third quarter. Assenagon Asset Management S.A. now owns 425,108 shares of the medical instruments supplier’s stock worth $3,307,000 after acquiring an additional 28,499 shares during the period. Ballentine Partners LLC bought a new position in AngioDynamics during the third quarter worth about $141,000. Finally, Wealth Enhancement Advisory Services LLC bought a new position in AngioDynamics during the third quarter worth about $86,000. 89.43% of the stock is owned by institutional investors.

AngioDynamics Trading Up 0.8 %

ANGO opened at $10.53 on Friday. The company’s 50 day moving average is $10.42 and its 200-day moving average is $8.30. AngioDynamics, Inc. has a 1-year low of $5.26 and a 1-year high of $13.50. The company has a market cap of $426.11 million, a P/E ratio of -1.87 and a beta of 0.60.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. The business had revenue of $72.90 million during the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The firm’s quarterly revenue was down .1% on a year-over-year basis. During the same quarter last year, the business earned ($0.05) EPS. On average, equities analysts forecast that AngioDynamics, Inc. will post -0.37 EPS for the current year.

Insider Activity at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the transaction, the senior vice president now owns 41,817 shares in the company, valued at approximately $514,767.27. This trade represents a 8.85 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Separately, HC Wainwright increased their price objective on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, January 10th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.